Evidence map›Paper›PMID 36685282›Full record

ArticleFrontiers in molecular biosciences2022

Targeted and untargeted metabolomic approach for GDM diagnosis.

Izabela Burzynska-Pedziwiatr, Danuta Dudzik, Anna Sansone, Beata Malachowska, Andrzej Zieleniak, Monika Zurawska-Klis, Carla Ferreri, Chryssostomos Chatgilialoglu, Katarzyna Cypryk, Lucyna A Wozniak and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Izabela Burzynska-PedziwiatrLaboratory of Metabolomic Studies, Department of Structural Biology, Medical University of Lodz, Lodz, Poland.
Danuta DudzikDepartment of Biopharmaceutics and Pharmacodynamics, Medical University of Gdansk, Gdansk, Poland.
Anna SansoneConsiglio Nazionale delle Ricerche, Institute for the Organic Synthesis and Photoreactivity, Bologna, Italy.
Beata MalachowskaDepartment of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland.
Andrzej ZieleniakLaboratory of Metabolomic Studies, Department of Structural Biology, Medical University of Lodz, Lodz, Poland.
Monika Zurawska-KlisDepartment of Radiation Oncology, Einstein College of Medicine, Bronx, NY, United States.
Carla FerreriConsiglio Nazionale delle Ricerche, Institute for the Organic Synthesis and Photoreactivity, Bologna, Italy.
Chryssostomos ChatgilialogluConsiglio Nazionale delle Ricerche, Institute for the Organic Synthesis and Photoreactivity, Bologna, Italy.
Katarzyna CyprykDepartment of Radiation Oncology, Einstein College of Medicine, Bronx, NY, United States.
Lucyna A WozniakLaboratory of Metabolomic Studies, Department of Structural Biology, Medical University of Lodz, Lodz, Poland.
Michal J MarkuszewskiDepartment of Biopharmaceutics and Pharmacodynamics, Medical University of Gdansk, Gdansk, Poland.
Malgorzata Bukowiecka-MatusiakLaboratory of Metabolomic Studies, Department of Structural Biology, Medical University of Lodz, Lodz, Poland.
Medical University of Lodz · PLInstitute of Organic Synthesis and Photoreactivity · ITAlbert Einstein College of Medicine · USGdańsk Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gestational diabetes mellitus (GDM) is a disorder which manifests itself for the first time during pregnancy and is mainly connected with glucose metabolism. It is also known that fatty acid profile changes in erythrocyte membranes and plasma could be associated with obesity and insulin resistance. These factors can lead to the development of diabetes. In the reported study, we applied the untargeted analysis of plasma in GDM against standard glucose-tolerant (NGT) women to identify the differences in metabolomic profiles between those groups. We found higher levels of 2-hydroxybutyric and 3-hydroxybutyric acids. Both secondary metabolites are associated with impaired glucose metabolism. However, they are products of different metabolic pathways. Additionally, we applied lipidomic profiling using gas chromatography to examine the fatty acid composition of cholesteryl esters in the plasma of GDM patients. Among the 14 measured fatty acids characterizing the representative plasma lipidomic cluster, myristic, oleic, arachidonic, and α-linoleic acids revealed statistically significant changes. Concentrations of both myristic acid, one of the saturated fatty acids (SFAs), and oleic acid, which belong to monounsaturated fatty acids (MUFAs), tend to decrease in GDM patients. In the case of polyunsaturated fatty acids (PUFAs), some of them tend to increase (e.g., arachidonic), and some of them tend to decrease (e.g., α-linolenic). Based on our results, we postulate the importance of hydroxybutyric acid derivatives, cholesteryl ester composition, and the oleic acid diminution in the pathophysiology of GDM. There are some evidence suggests that the oleic acid can have the protective role in diabetes onset. However, metabolic alterations that lead to the onset of GDM are complex; therefore, further studies are needed to confirm our observations.

Indexed as

biomarkerscholesteryl estersGDMlipidomic profilinguntargeted metabolomics

Identifiers

PMID36685282
PMCPMC9849575
OpenAlexW4313574458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.